Lombardi Cancer Center Georgetown University Washington, DC
|
|
- Sheryl Baker
- 5 years ago
- Views:
Transcription
1 Lombardi Cancer Center Georgetown University Washington, DC
2 Lombardi Cancer Center Georgetown University Washington, DC microrna and other nucleic acids analysis in liquid biopsies Anton Wellstein World CDx Boston, Sept 8-11, 2015
3 Disclosures: Inventor on Georgetown University filed patents related to the topic Member of the Scientific Advisory Board of Indivumed Inc.
4 DNA mrnas + 3 x 10 4 genes mrnas Proteins > modified Metabolites + 5 x 10 3 Phenotype
5 DNA mrnas + 3 x 10 4 genes mrnas micrornas Proteins > modified Metabolites + 5 x 10 3 Phenotype
6 microrna = mir 1993 two reports that a small (= micro) RNA modulates expression of a protein in the nematode C. elegans 2002 initial reports of a potential role of micrornas in cancer
7 mirna genes: Human 1,424 Mouse 720 Zebrafish 358 Berezikov Nat Rev Genetics 2011
8 micrornas microrna expression patterns in normal vs cancer tissues Colon Pros Brst ColonCa ProCa BrCa normal tissues cancer tissues Lu et al. Nature 435:834, 2005
9 microrna versus mrna expression patterns in normal human tissues ( 89 different epithelial tissues) Lu et al. Nature 435:834, 2005
10 2008
11 2008
12 Nature Methods 2011
13 2007; Vol. 9:654-9
14 2011; Vol. 13: ; Vol. 9:654-9
15 What is in a liquid biopsy? plasma buffy coat (leukocytes) erythrocytes, platelets cell-free: DNA microrna proteins metabolites Vietsch et al Pancreat Disord Ther 5:22; 2015
16 What is in a liquid biopsy? plasma buffy coat (leukocytes) erythrocytes, platelets cell-free: DNA microrna proteins metabolites + cancer cells cancer cells stroma Vietsch et al Pancreat Disord Ther 5:22; 2015
17 Detect metastatic disease in early stage cancer? plasma buffy coat (leukocytes) erythrocytes, platelets cell-free: DNA microrna proteins metabolites + cancer cells cancer cells stroma Vietsch et al Pancreat Disord Ther 5:22; 2015
18 serum before the initial surgery of stage I/II colon cancer Shivapurkar et al PLoS One 2014 e84686
19 Shivapurkar et al PLoS One 2014 e84686
20 The usual suspects approach... Shivapurkar et al PLoS One 2014 e84686
21 B Genome wide mir serum profile one patient with one without recurrent disease RC NRC hsa-mi-378 hsa-mir-92a hsa-mir-185 hsa-mir-1979 hsa-mir-25 hsa-mir-1977 hsa-mir-320a hsa-mir-1246 hsa-mir-320b hsa-mir-1974 hsa-mir-424 hsa-mir-374a hsa-mir-486-5p hsa-mir-223 hsa-mir-1274b hsa-mir-20b hsa-mir-126 hsa-mir-195 hsa-mir-451 hsa-mir-16 hsa-mir-103 hsa-mir-17 hsa-mir-140-3p hsa-mir-191 hsa-let-7c hsa-mir-15a hsa-mir-135a hsa-mir-1290 hsa-mir-1307 hsa-mir-30e hsa-mir-376a hsa-mir-26b hsa-mir-425 hsa-mir-29c hsa-mir-106b hsa-mir-107 hsa-mir-23b hsa-mir-494 hsa-mir-92b hsa-mir-192 hsa-mir-151-3p hsa-mir-320c hsa-mir-342-5p hsa-mir-122 hsa-mir-320d hsa-mir-30d hsa-mir-142-3p hsa-mir-150 hsa-mir-1975 hsa-mir-106a hsa-mir-19a hsa-mir-19b hsa-mir-374b hsa-mir-30a hsa-mir-135b hsa-mir-1274a hsa-mir-93 hsa-let-7b hsa-mir-15b hsa-mir-532-3p hsa-mir-221 hsa-mir-125a-5p hsa-mir-615-5p hsa-mir-1260 hsa-mir-596 hsa-mir-1287 hsa-mir-1915 hsa-mir-23a hsa-mir-21 hsa-mir-101 Shivapurkar et al PLoS One 2014 e84686
22 Shivapurkar et al PLoS One 2014 e84686
23 Shivapurkar et al PLoS One 2014 e84686
24 Shivapurkar et al PLoS One 2014 e84686
25 Shivapurkar et al PLoS One 2014 e84686
26 Monitor treatment response? plasma buffy coat (leukocytes) erythrocytes, platelets cell-free: DNA microrna proteins metabolites + cancer cells cancer cells stroma Vietsch et al Pancreat Disord Ther 5:22; 2015
27 LaConti et al PLoS One e20687
28 Analysis of micrornas during PanCa progression ( Kras mutant model ) micrornas qrt-pcr animal model P48Cre x LSL/KrasG12D patients pancreatic cancer initiation and progression
29 Analysis of micrornas during PanCa progression ( Kras mutant model ) LaConti et al PLoS One e20687
30 Analysis of micrornas during PanCa progression ( Kras mutant model ) LaConti et al PLoS One e20687
31 micrornas in the circulation & gemcitabine treatment mouse mutant K-ras Panc Ca model blood samples diagnosis profile treatment blood samples response profile micrornas
32 micrornas in the circulation & gemcitabine treatment mouse mutant K-ras Panc Ca model LaConti et al PLoS One e20687
33 micrornas in the circulation & gemcitabine treatment mouse mutant K-ras Panc Ca model LaConti et al PLoS One e20687
34 Shivapurkar et al Int J Colorectal Dis
35 Circulating mir patterns in patients with pancreatic cancer treatment with capecitabine & lapatinib different times of treatment ( n=8 ) Tian, Shivapurkar et al Oncology Letters in press
36 Circulating mir patterns in patients with pancreatic cancer treatment with capecitabine & lapatinib different times of treatment ( n=8 ) Tian, Shivapurkar et al Oncology Letters in press
37 Evolutionary selection of cancer cell populations with distinct drivers of malignant progression
38 Evolutionary selection of cancer cell populations with distinct drivers of malignant progression from: Yates, Nature Rev Genetics 2012
39 Monitor the evolutionary selection of cancer cell populations / treatment response plasma buffy coat (leukocytes) erythrocytes, platelets cell-free: DNA microrna proteins metabolites + cancer cells cancer cells stroma Vietsch et al Pancreat Disord Ther 5:22; 2015
40 Food for Thought: Bad Tumor Markers Are Equal to Bad Drugs Daniel F. Hayes, MD U Mich, Ann Arbor
41 Ivana Peran Eveline Vietsch Anne Deslattes Joe LaConti Anna T Riegel Narayan Shivapurkar John Marshall Louis Weiner Claudine Isaacs Ruth A He Hartmut Juhl, Indivumed Hamburg, Germany Casper van Eijck, Erasmus U Rotterdam, Netherlands
42 Ivana Peran Eveline Vietsch
MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationLiquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director
Liquid Biopsy Jesus Garcia-Foncillas MD PhD Director Main issues about liquid biopsies New paradigm: Precision Medicine Heterogeneity & Dynamics Surrogate mirror for the tumor CTCs in colon cancer ctdna:
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationdeveloping new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success
micrornas developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success Dr. Carola Wagner IMGM Laboratories GmbH Martinsried, Germany qpcr 2009 Symposium
More informationmicrorna analysis Merete Molton Worren Ståle Nygård
microrna analysis Merete Molton Worren Ståle Nygård Help personnel: Daniel Vodak Background Dysregulation of mirna expression has been connected to progression and development of atherosclerosis The hypothesis:
More informationMEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
More informationClasificación Molecular del Cáncer de Próstata. JM Piulats
Clasificación Molecular del Cáncer de Próstata JM Piulats Introduction The Gleason score is the major method for prostate cancer tissue grading and the most important prognostic factor in this disease.
More informationThe clinical relevance of circulating, cell-free and exosomal micrornas as biomarkers for gynecological tumors
Department of Tumor Biology The clinical relevance of circulating, cell-free and exosomal micrornas as biomarkers for gynecological tumors cfdna Copenhagen April 6-7, 2017 Heidi Schwarzenbach, PhD Tumor
More informationSupplementary materials and methods.
Supplementary materials and methods. Microarray printing and data analysis. The LNA-modified oligonucleotide probe set for all annotated mirnas from mouse (Mus musculus) and human (Homo sapiens) in the
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationQué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
More informationA two-microrna signature in urinary exosomes for diagnosis of prostate cancer
Poster # B4 A two-microrna signature in urinary exosomes for diagnosis of prostate cancer Anne Karin Ildor Rasmussen 1, Peter Mouritzen 1, Karina Dalsgaard Sørensen 3, Thorarinn Blondal 1, Jörg Krummheuer
More informationmicrorna-200b and microrna-200c promote colorectal cancer cell proliferation via
Supplementary Materials microrna-200b and microrna-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs Supplementary Table 1.
More informationccfdna Webinar Series: The Basics and Beyond
ccfdna Webinar Series: The Basics and Beyond Part I Maxwell RSC ccfdna Plasma Kit and Maxwell RSC instrument are For Research Use Only. Not for Use in Diagnostic Procedures. Introduction to Circulating,
More informationNanotechnology applications in medical diagnosis, imaging, and therapy
Engineering Conferences International ECI Digital Archives Nanotechnology in Medicine: From Molecules to Humans Proceedings 7-4-2016 Nanotechnology applications in medical diagnosis, imaging, and therapy
More informationAndreas Wicki. University Hospital Basel Switzerland
Andreas Wicki University Hospital Basel Switzerland Disclosures Funding of research projects: Piqur Therapeutics Consultancy: Actelion Pharmaceuticals Predictive Biomarkers for Targeted Therapy in Oncology
More information7th November, Translational Science: how to move from biology to clinical applications
7th November, 2014 Translational Science: how to move from biology to clinical applications 1 Translational science: How to move from biology to clinical applications Translational cancer genomics and
More informationProducts for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma
MACHEREY-NAGEL Products for cfdna and mirna isolation Bioanalysis Subhead Circulating Cover nucleic acids from plasma n Flexible solutions for small and large blood plasma volumes n Highly efficient recovery
More informationCirculating tumor cells/dna/etc for Radiation Oncologists
Circulating tumor cells/dna/etc for Radiation Oncologists Andrew Z. Wang, M.D. Associate Professor Director of Clinical and Translational Research Department of Radiation Oncology Carolina Center for Cancer
More informationApril 5, :45 AM 1:45 PM MARRIOTT MARQUIS HOTEL & MARINA, MIRAMAR VIGNETTE 1 VIGNETTE 2 VIGNETTE 3* VIGNETTE 4* VIGNETTE 5*
April 5, 2016 11:45 AM 1:45 PM MARRIOTT MARQUIS HOTEL & MARINA, MIRAMAR CHAIR: DANNY A. MILNER, JR., BRIGHAM & WOMEN S HOSPITAL, BOSTON, MA VIGNETTE 1 VIGNETTE 2 VIGNETTE 3* VIGNETTE 4* VIGNETTE 5* *VIGNETTES
More informationColorectal cancer: pathology
UK NEQAS for Molecular Pathology Colorectal cancer: pathology Nick West Pathology & Tumour Biology May 2013 Colorectal cancer (CRC) 40,695 new cases in 2010 15,708 deaths Management of CRC Surgery Main
More information(,, ) microrna(mirna) 19~25 nt RNA, RNA mirna mirna,, ;, mirna mirna. : microrna (mirna); ; ; ; : R321.1 : A : X(2015)
35 1 Vol.35 No.1 2015 1 Jan. 2015 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2015.01.0037 E-mail: randc_journal@163.com microrna ( 450052) microrna() 19~25 nt RNA RNA ; : microrna (); ;
More informationPros and cons of liquid biopsy: Ready to replace tissue?
Pros and cons of liquid biopsy: Ready to replace tissue? 2-Day Molecular Biologists Symposium: Liquid biopsies Federico Rojo Enterprise Interest No disclosures. Biological limitations for molecular testing:
More informationPiastrine: genoma e trascrittoma. Paolo Gresele Department of Medicine Section of Internal and Cardiovascular Medicine University of Perugia
Piastrine: genoma e trascrittoma Paolo Gresele Department of Medicine Section of Internal and Cardiovascular Medicine University of Perugia Workshop post-isth: novità dal meeting di Toronto 2015 Bergamo,
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More informationBenchmark study: Exiqon mircury LNA microrna arrays vs. Supplier A s DNA based capture probes. Includes comparison of:
Benchmark study: Exiqon mircury LNA microrna arrays vs. Supplier A s DNA based capture probes Includes comparison of: I. II. III. Signal levels Relative quantification False differences For complete experimental
More informationSupplementary Figure 1
Supplementary Figure 1 a Location of GUUUCA motif relative to RNA position 4e+05 3e+05 Reads 2e+05 1e+05 0e+00 35 40 45 50 55 60 65 Distance upstream b 1: Egg 2: L3 3: Adult 4: HES 4e+05 3e+05 2e+05 start
More informationMarta Puerto Plasencia. microrna sponges
Marta Puerto Plasencia microrna sponges Introduction microrna CircularRNA Publications Conclusions The most well-studied regions in the human genome belong to proteincoding genes. Coding exons are 1.5%
More informationVUmc. VU University Medical Center, Amsterdam, The Netherlands University of Pisa, Pisa, Italy
MicroRNA-21 (mir-21) in pancreatic adenocarcinoma: correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity Elisa Giovannetti, Niccola
More informationType of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic
More informationIntegrated platform for liquid biopsy-based personalized cancer medicine
Integrated platform for liquid biopsy-based personalized cancer medicine Dr. Bernhard Polzer Fraunhofer ITEM-Regensburg Personalized Tumor Therapy Personalized cancer therapy Primary tumor single tumor
More informationhe micrornas of Caenorhabditis elegans (Lim et al. Genes & Development 2003)
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function (D. Bartel Cell 2004) he micrornas of Caenorhabditis elegans (Lim et al. Genes & Development 2003) Vertebrate MicroRNA Genes (Lim et al. Science
More informationmir-509-5p and mir-1243 increase the sensitivity to gemcitabine by inhibiting
mir-509-5p and mir-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer Hidekazu Hiramoto, M.D. 1,3, Tomoki Muramatsu, Ph.D. 1, Daisuke Ichikawa,
More informationVantage Diabetes Panel 1
Catalog No. AM100050 50 Reactions To be used in conjunction with the Vantage microrna Detection Kit, catalog number AM100091 (50 reactions) or AM100092 (200 reactions). Components included in this kit:
More informationOverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA
OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.
More informationPCT WO 2009/ Al
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International
More informationClinical Development for Patients with Cancer
OMP 59R5: a Novel Therapeutic Antibody in Clinical Development for Patients with Cancer Jakob Dupont, MD, MA Chief Medical Officer and Senior Vice President OncoMed Pharmaceuticals Inc. Adjunct Clinical
More informationCirculating Tumor Cells (CTC) Technologies
Table of Contents MIR036 I. SCOPE AND METHODOLOGY Scope of the Study Analytics and data presented in this report pertain to several parameters such as - Research Methodology This report is uniquely researched
More informationSupplementary Material
Supplementary Material Summary: The supplementary information includes 1 table (Table S1) and 4 figures (Figure S1 to S4). Supplementary Figure Legends Figure S1 RTL-bearing nude mouse model. (A) Tumor
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes The need for improved diagnostics At the advanced edge of oncology, rapid access to accurate data on disease state is vital. Current technologies such as
More informationomiras: MicroRNA regulation of gene expression
omiras: MicroRNA regulation of gene expression Sören Müller, Goethe University of Frankfurt am Main Molecular Bioinformatics Group, Institute of Computer Science Plant Molecular Biology Group, Institute
More informationmicrorna PCR System (Exiqon), following the manufacturer s instructions. In brief, 10ng of
SUPPLEMENTAL MATERIALS AND METHODS Quantitative RT-PCR Quantitative RT-PCR analysis was performed using the Universal mircury LNA TM microrna PCR System (Exiqon), following the manufacturer s instructions.
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationCellecta Overview. Started Operations in 2007 Headquarters: Mountain View, CA
Cellecta Overview Started Operations in 2007 Headquarters: Mountain View, CA Focus: Development of flexible, scalable, and broadly parallel genetic screening assays to expedite the discovery and characterization
More informationADVANCES IN FAECAL DNA TESTING FOR COLORECTAL CANCER SCREENING: A LITERATURE REVIEW FOR PRIMARY CARE PROVIDERS
ADVANCES IN FAECAL DNA TESTING FOR COLORECTAL CANCER SCREENING: A LITERATURE REVIEW FOR PRIMARY CARE PROVIDERS *Louise Babikow, Adelle Grant McAuley, Jenny Calhoun University of Pennsylvania, Philadelphia,
More informationThe mir-199a/brm/egr1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines
Supplementary information Supplementary Figure -9 Supplementary Table -4 The mir-99a/brm/egr axis is a determinant of anchorage-independent growth in epithelial tumor cell lines Kazuyoshi Kobayashi, Kouhei
More informationSupporting Information
Supporting Information Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy Chi-Hsiu Liu 1, Zhongxiao Wang 1, Ye Sun 1, John Paul SanGiovanni 2, Jing Chen 1, * 1 Department
More informationMilk micro-rna information and lactation
Christophe Lefèvre, BioDeakin,. Deakin University, Geelong VIC Australia Milk micro-rna information and lactation New Signals in milk? - Markers of milk and lactation status? - Signal infant development?
More informationSantosh Patnaik, MD, PhD! Assistant Member! Department of Thoracic Surgery! Roswell Park Cancer Institute!
Santosh Patnaik, MD, PhD Assistant Member Department of Thoracic Surgery Roswell Park Cancer Institute MicroRNA biology, techniques and applications History Biogenesis Nomenclature Tissue specificity Mechanisms
More informationGENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2
SYNDROME BRCA1 BRCA2 Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationJohn Bell Centre for Innovative Cancer Therapeutics
Enhancing Oncolytic Virus Activity by Engineering of Artificial micrornas John Bell Centre for Innovative Cancer Therapeutics Affiliated with Affilié à 1 Oncolytic Viruses: A Therapy for Metastatic Cancers?
More informationDeciphering the Role of micrornas in BRD4-NUT Fusion Gene Induced NUT Midline Carcinoma
www.bioinformation.net Volume 13(6) Hypothesis Deciphering the Role of micrornas in BRD4-NUT Fusion Gene Induced NUT Midline Carcinoma Ekta Pathak 1, Bhavya 1, Divya Mishra 1, Neelam Atri 1, 2, Rajeev
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/7/310/ra11/dc1 Supplementary Materials for STAT3 Induction of mir-146b Forms a Feedback Loop to Inhibit the NF-κB to IL-6 Signaling Axis and STAT3-Driven Cancer
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationNon-Invasive Array Based Screening for Cancer. Dr. Amit Kumar President and CEO CombiMatrix Corporation
Non-Invasive Array Based Screening for Cancer Dr. Amit Kumar President and CEO CombiMatrix Corporation www.combimatrix.com May 13, 2009 This presentation contains forward-looking statements within the
More informationNeoplasia 2018 lecture 11. Dr H Awad FRCPath
Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even
More informationNext Generation Cancer Diagnostics For First Time Right Therapy Choice. Anja van de Stolpe
Next Generation Cancer Diagnostics For First Time Right Therapy Choice Anja van de Stolpe Paradigm shift in cancer treatment towards personalized treatment Chemotherapy for all therapy targeting cancer
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationResidual Cancer. May 3-5, International Symposium. on Minimal. Le Corum. > Preliminary. Program MONTPELLIER, FRANCE
International Symposium th on Minimal Residual Cancer > Preliminary Program May 3-5, 2018 Le Corum MONTPELLIER, FRANCE Organizers: www.ismrc2018.com > Committee & Speakers > Welcome to Montpellier Scientific
More informationSet the stage: Genomics technology. Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands
Set the stage: Genomics technology Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands Amendment to the latest consolidated version of the REACH legislation REACH Regulation 1907/2006:
More informationmicrornas (mirna) and Biomarkers
micrornas (mirna) and Biomarkers Small RNAs Make Big Splash mirnas & Genome Function Biomarkers in Cancer Future Prospects Javed Khan M.D. National Cancer Institute EORTC-NCI-ASCO November 2007 The Human
More informationBlood Based Screening
Plenary Session 4 CRC screening: The best modality is... Blood Based Screening Molnár, Béla M.D., PhD 2nd Dept. of Medicine Semmelweis Budapest Hungary There is no controversy: screening saves lives Irrefutable
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationCUP: Treatment by molecular profiling
CUP: Treatment by molecular profiling George Pentheroudakis Professor of Oncology Medical School, University of Ioannina Greece Chair, ESMO Guidelines September 2018 Enterprise Interest No disclosures.
More informationCancer Biology Course. Invasion and Metastasis
Cancer Biology Course Invasion and Metastasis 2016 Lu-Hai Wang NHRI Cancer metastasis Major problem: main reason for killing cancer patients, without it cancer can be cured or controlled. Challenging questions:
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationMicroRNAs: novel regulators in skin research
MicroRNAs: novel regulators in skin research Eniko Sonkoly, Andor Pivarcsi KI, Department of Medicine, Unit of Dermatology and Venerology What are micrornas? Small, ~21-mer RNAs 1993: The first mirna discovered,
More informationYoungnam Cho. National Cancer Center Biomarker Branch
Youngnam Cho National Cancer Center Biomarker Branch Contents 1. Liquid Biopsy 2. Circulating Tumor Cells from Blood 3. Cell-free DNA from Blood 1. Liquid biopsy Cancer Diagnosis IMAGING TISSUE BIOPSY
More informationMicroRNAs: a new source of biomarkers in radiation response. Simone Moertl, Helmholtz Centre Munich
MicroRNAs: a new source of biomarkers in radiation response Simone Moertl, Helmholtz Centre Munich The RNA World mrna rrna coding snorna trna scarna RNA snrna noncoding lincrna rasirna RNAi anti-sense
More informationHALLA KABAT * Outreach Program, mircore, 2929 Plymouth Rd. Ann Arbor, MI 48105, USA LEO TUNKLE *
CERNA SEARCH METHOD IDENTIFIED A MET-ACTIVATED SUBGROUP AMONG EGFR DNA AMPLIFIED LUNG ADENOCARCINOMA PATIENTS HALLA KABAT * Outreach Program, mircore, 2929 Plymouth Rd. Ann Arbor, MI 48105, USA Email:
More informationDepartment of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA 2
Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery Systems Mei-Ju Su 1, Hibah Aldawsari 2, and Mansoor Amiji
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationSUPPLEMENTARY INFORMATION
DOI:.38/ncb3399 a b c d FSP DAPI 5mm mm 5mm 5mm e Correspond to melanoma in-situ Figure a DCT FSP- f MITF mm mm MlanaA melanoma in-situ DCT 5mm FSP- mm mm mm mm mm g melanoma in-situ MITF MlanaA mm mm
More informationTitle page. Title: MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in
Title page Title: MicroRNA- Controls Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma Authors Manabu Mikamori, Daisaku Yamada, Hidetoshi Eguchi, Shinichiro Hasegawa, Tomoya
More information(A) Cells grown in monolayer were fixed and stained for surfactant protein-c (SPC,
Supplemental Figure Legends Figure S1. Cell line characterization (A) Cells grown in monolayer were fixed and stained for surfactant protein-c (SPC, green) and co-stained with DAPI to visualize the nuclei.
More informationGene Regulation Part 2
Michael Cummings Chapter 9 Gene Regulation Part 2 David Reisman University of South Carolina Other topics in Chp 9 Part 2 Protein folding diseases Most diseases are caused by mutations in the DNA that
More informationSmall RNA-Seq and profiling
Small RNA-Seq and profiling Y. Hoogstrate 1,2 1 Department of Bioinformatics & Department of Urology ErasmusMC, Rotterdam 2 CTMM Translational Research IT (TraIT) BioSB: 5th RNA-seq data analysis course,
More informationEnterprise Interest No
Enterprise Interest No SY-05 Pulmonary Pathology: Options for targeted therapy in lung cancer Liquid biopsy in thoracic oncology Where are we now? Paul Hofman Laboratory of Clinical and Experimental Pathology
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationThursday, March 17, pm ET
Virtual Molecular Tumor Board Host: MedStar Georgetown University Hospital Leader: Dr. John Marshall Thursday, March 17, 2016 5 pm ET Patient 1 The information contained in these slides is provided for
More informationWhat do liquid biopsies offer us for breast cancer patients?
What do liquid biopsies offer us for breast cancer patients? Isaac Garcia-Murillas Breast Cancer Now Research Centre, The institute of Cancer Research, London, UK Molecular Analysis of breast cancer Invasive
More informationThe 100,000 Genomes Project
The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London Genomics England
More informationSynthetic microrna Reference Standards Genomics Research Group ABRF 2015
Synthetic microrna Reference Standards Genomics Research Group ABRF 2015 Don A. Baldwin, Ph.D. support@signalbiology.com Reference samples for Platform evaluation Protocol development Assay service improvement
More informationDihydropyrimidine Dehydrogenase (DPYD) Pharmacogenetic Competency
Dihydropyrimidine Dehydrogenase (DPYD) Pharmacogenetic Competency Updated on 6/2015 Pre-test Question # 1 A patient has a reported pharmacogenetic test result of DPYD *1/*2. What is the assigned phenotype?
More informationSSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer.
Supplementary Figure 1 SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer. Scatter plots comparing expression profiles of matched pretreatment
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationcirculating nucleic acids in pdf Circulating nucleic acids in plasma and serum: diagnosis QIAamp Circulating Nucleic Acid Handbook - Qiagen
DOWNLOAD OR READ : CIRCULATING NUCLEIC ACIDS IN EARLY DIAGNOSIS PROGNOSIS AND TREATMENT MONITORING AN INTRODUCTION ADVANCES IN PREDICTIVE PREVENTIVE AND PERSONALISED MEDICINE PDF EBOOK EPUB MOBI Page 1
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationCancer Problems in Indonesia
mirna and Cancer : mirna as a Key Regulator in Cancer Sofia Mubarika 2 nd Symposium Biomolecular Update in Cancer PERABOI Padang 18 Mei 2013 Cancer Problems in Indonesia 1. Chemoresistency / recurrency
More informationCardiovascular. Diseases. a simple and standardized kit qpcr analysis of circulating platelet-derived micrornas
microrna Biomarkers of Platelet Function Neurodegenerative Diseases Cardiovascular Diseases Musculoskeletal Diseases a simple and standardized kit qpcr analysis of circulating platelet-derived micrornas
More informationRNA-seq Introduction
RNA-seq Introduction DNA is the same in all cells but which RNAs that is present is different in all cells There is a wide variety of different functional RNAs Which RNAs (and sometimes then translated
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationFUTURE PERSPECTIVES OF CIRCULATING TUMOR DNA IN COLORECTAL CANCER
FUTURE PERSPECTIVES OF CIRCULATING TUMOR DNA IN COLORECTAL CANCER C. NADAL 1-3, T. WINDER 4, A. GERGER 5-6, D. TOUGERON 7-8 SELECTED HIGHLIGHTS 1 Medical Oncology Department, Institut Clínic de Malalties
More informationmicrorna Therapeutics Heading Towards the Clinic
GENReports: Market & Tech Analysis microrna Therapeutics Heading Towards the Clinic > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us Topic Introduction and Scope
More information